Skip to content
Peptide research

PT-141 (Bremelanotide)

Also known as Vyleesi
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
FDA-approved

PT-141 (Bremelanotide) is a synthetic melanocortin agonist marketed off-label for low libido and ED. Evidence is strongest in women with HSDD, weaker for male ED, and speculative for appetite effects. Key risks include nausea in about 40%, potentially persistent focal skin hyperpigmentation, and transient blood-pressure increases. Uncontrolled hypertension and known cardiovascular disease are contraindications. It is FDA-approved only as a branded HSDD drug for women; compounded versions are subject to pharmacy and drug laws but are not FDA-approved or reviewed before marketing for safety, effectiveness and quality.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Vyleesi (bremelanotide / PT-141) is the first and only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, approved in 2019. It is a synthetic seven-amino-acid peptide derived from Melanotan II that works in the brain rather than the body -- unlike Viagra-type drugs that increase blood flow, Vyleesi activates melanocortin receptors (MC3R/MC4R) in the hypothalamus to directly stimulate the neural pathways responsible for sexual desire and arousal. It is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity.

How it works in the body

Activates MC3R and MC4R melanocortin receptors in the hypothalamus, triggering sexual arousal through central nervous system pathways rather than vascular mechanisms. Unlike PDE5 inhibitors (Viagra), it works on desire and arousal in the brain, not just blood flow to genitals.

Research overview

Bremelanotide was developed from alpha-MSH (a natural hormone) through the Melanotan II research program at the University of Arizona. It activates MC3R and MC4R receptors in the brain's hypothalamus, modulating dopamine pathways involved in sexual desire -- a fundamentally different mechanism from PDE5 inhibitors like Viagra that target blood flow. Clinical trials leading to FDA approval demonstrated statistically significant improvements in sexual desire and reduction of distress related to low desire in premenopausal women with HSDD. Common side effects include nausea, flushing, and headache. Research has also explored its effects on appetite suppression and, in early studies, anti-glioblastoma activity, though these remain investigational.

Who researches PT-141 (Bremelanotide)?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People exploring hormone and sexual health

    Researched for effects on hormone levels, sexual function, or fertility.

  • People researching experimental oncology peptides

    Studied for effects on cancer cell targeting or tumor biology in preclinical research.

Important considerations for

  • Those with Uncontrolled hypertension

    Absolute

    FDA label: causes transient blood pressure increases. Contraindicated in uncontrolled hypertension.

  • Those with Cardiovascular disease

    High

    FDA label: not recommended in patients with cardiovascular disease due to BP effects.

  • Those who are pregnant or breastfeeding

    Absolute

    FDA Pregnancy Category X equivalent. May cause fetal harm.

Safety & interactions

Do not use if

  • Uncontrolled hypertension

    Absolute

    FDA label: causes transient blood pressure increases. Contraindicated in uncontrolled hypertension.

  • Cardiovascular disease

    High

    Known cardiovascular disease is an absolute contraindication in the FDA label. Patients at high cardiovascular risk are a separate group for whom use is not recommended.

General cautions

  • Pregnancy

    Absolute

    Pregnancy precaution: human data are insufficient, and animal studies indicate potential fetal harm. Use effective contraception and discontinue Vyleesi if pregnancy is suspected.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Nausea (40% of patients — manageable with antiemetics)

    High

    VYLEESI label, Adverse Reactions 6.1 / Warnings and Precautions 5.3 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Flushing (20%), headache (11%)

    Moderate

    VYLEESI label, Adverse Reactions 6.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Transient blood pressure increase (~6/3 mmHg, peaks 2-4h, resolves 12h)

    Moderate

    VYLEESI label, Warnings and Precautions 5.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Focal skin hyperpigmentation (1% with labeled use, >33% with daily use, may be permanent)

    Moderate

    VYLEESI label, Warnings and Precautions 5.2 / Dosage and Administration 2.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Contraindicated: uncontrolled hypertension, cardiovascular disease

    High

    VYLEESI label, Contraindications 4 / Warnings and Precautions 5.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Not recommended during pregnancy

    Moderate

    VYLEESI label, Use in Specific Populations 8.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

Interaction summary(8)

Rated by direction with this peptide

  • Uncontrolled hypertension / known cardiovascular disease (clinical condition)

    CautionHigh

    An absolute FDA contraindication — the 2-to-4-hour pressor effect (~6/3 mmHg, with heart rate down up to 5 bpm) is unacceptable in patients with uncontrolled blood pressure or established cardiovascular disease, and blood pressure must be well-controlled before any dose. The label also states the drug is not recommended in patients at high cardiovascular risk.

    VYLEESI label, Contraindications 4 / Warnings and Precautions 5.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Oral naltrexone (and naltrexone-containing products)

    CautionHigh

    The label states that bremelanotide may significantly decrease the systemic exposure of orally administered naltrexone, and that patients should avoid using it with oral naltrexone products intended to treat alcohol or opioid addiction because of the severe consequence of naltrexone treatment failure.

    VYLEESI label, Drug Interactions 7.2 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Orally administered drugs generally, especially those needing a threshold concentration (e.g., antibiotics)

    CautionModerate

    Bremelanotide may slow gastric emptying and reduce the rate and extent of absorption of concomitant oral medications; the label instructs patients to avoid using it when taking oral drugs that depend on threshold concentrations for efficacy, such as antibiotics.

    VYLEESI label, Drug Interactions 7.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Indomethacin (and NSAIDs taken orally for acute effect)

    CautionLow

    The label names indomethacin as its example of a drug whose effect may be delayed via the gastric-emptying mechanism, advising patients to consider discontinuing bremelanotide if a concomitant oral drug needing quick onset (e.g., pain relief) is delayed. Clinically minor but worth noting around dosing.

    VYLEESI label, Drug Interactions 7.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • PDE5 inhibitors (sildenafil, tadalafil)

    CautionModerate

    Efficacy synergy has been reported only once, in a phase 2 study of low-dose INTRANASAL PT-141 plus sildenafil (the separate sildenafil-non-responder trial used bremelanotide alone, not the combination). Against that, the two drugs have opposing hemodynamic effects, the combination has never been characterized for the approved subcutaneous product, the population using PDE5 inhibitors is exactly the cardiovascularly at-risk group the label restricts, and any such use is off-label. The net direction is caution, not synergy.

    PMID 15833522 (combination, intranasal, phase 2) https://pubmed.ncbi.nlm.nih.gov/15833522/ ; PMID 18206919 (monotherapy in sildenafil failures) https://pubmed.ncbi.nlm.nih.gov/18206919/ ; VYLEESI label Warnings 5.1 (no PDE5 interaction study exists)

  • Antihypertensive medications

    CautionModerate

    No formal drug-interaction study exists and this is a pharmacodynamic inference, but the documented transient pressor effect works against antihypertensive therapy and the label's contraindication in uncontrolled hypertension means patients on treatment need documented control and periodic monitoring rather than assumed safety.

    VYLEESI label, Warnings and Precautions 5.1 / Contraindications 4 (no dedicated interaction study; PD inference) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Ondansetron and other prophylactic antiemetics

    NeutralLow

    In a phase 4, placebo-controlled study of 228 healthy women randomized to oral ondansetron or placebo 30 minutes before a single subcutaneous bremelanotide injection, ondansetron pre-treatment did not reduce the incidence of bremelanotide-associated nausea. Antiemetic prophylaxis should not be relied on as a mitigation strategy. (Extension to antiemetics of other classes is inference — only ondansetron was tested.)

    VYLEESI label, Adverse Reactions 6.1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Other melanocortin agonists (melanotan II, afamelanotide, setmelanotide)

    CautionTheoretical

    No interaction studies exist. Purely mechanism-based: using MC1R/MC4R agonists together would be expected to add to melanocyte stimulation and focal hyperpigmentation, and potentially blood pressure effects — a real-world concern given melanotan II's circulation in the same peptide market. Flagged Theoretical precisely because no human co-administration data exist.

    Mechanism-based inference; no primary interaction study identified in PubMed or the VYLEESI label.

Known risks(6)

  • Nausea (40% of patients — manageable with antiemetics)

  • Flushing (20%), headache (11%)

  • Transient blood pressure increase (~6/3 mmHg, peaks 2-4h, resolves 12h)

  • Focal skin hyperpigmentation (1% with labeled use, >33% with daily use, may be permanent)

  • Contraindicated: uncontrolled hypertension, cardiovascular disease

  • Not recommended during pregnancy

Drug interactions(4)

  • Melanotan II

    PT-141 is derived from MT-II. Both are melanocortin agonists. Combining amplifies side effects.

  • PDE5 inhibitors (Viagra, Cialis)

    Different mechanisms but both affect sexual function/hemodynamics. Combining may cause additive BP effects.

  • Antihypertensives

    PT-141 causes transient BP increase +6/3mmHg. Monitor when combined.

  • Naltrexone

    Flibanserin (another HSDD drug) interacts with PT-141 is unknown. Avoid combining HSDD treatments.

Research & benefits

Evidence base

Evidence Level
Level 1 — FDA Approved
Total Studies
43
Human Participants
3500

43 completed studies, ~3,500 participants. Two pivotal RECONNECT Phase 3 trials (n=1,247) + 52-week extension (n=684). Phase 2 in male ED. Phase 1 weight loss. Nausea 40%, flushing 20%, headache 11%. BP +6/3 mmHg transient.

Researched for(6)

Rated by confidence in the evidence

  • HSDD treatment (women)

    High

    FDA-approved for HSDD, backed by two replicated 24-week phase 3 randomized placebo-controlled trials.

    PMID 31599840 (Kingsberg SA et al., Obstet Gynecol 2019;134(5):899-908) https://pubmed.ncbi.nlm.nih.gov/31599840/ ; FDA/DailyMed VYLEESI label https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

  • Erectile dysfunction (men)

    Medium

    Early controlled studies tested both intranasal and subcutaneous PT-141 in men; use in men remains off-label.

    PMID 18206919 (Safarinejad & Hosseini, J Urol 2008 — bremelanotide monotherapy in sildenafil failures) https://pubmed.ncbi.nlm.nih.gov/18206919/ ; PMID 15833522 (Diamond et al., Urology 2005 — PT-141 + sildenafil co-administration) https://pubmed.ncbi.nlm.nih.gov/15833522/

  • Sexual arousal (women)

    Medium

    Small randomized trials suggest an effect, but phase 3 trials targeted desire, not arousal.

    PMID 16839319 (Diamond LE et al., J Sex Med 2006) https://pubmed.ncbi.nlm.nih.gov/16839319/ ; PMID 27181790 (Clayton AH et al., Womens Health (Lond) 2016 — phase 2 dose-finding) https://pubmed.ncbi.nlm.nih.gov/27181790/

  • Appetite suppression

    Low

    Two short phase 1 randomized trials in women with obesity found reduced calorie intake and body weight; lasting weight-management benefits remain unestablished.

    Spana et al. 2022, Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. PMID 35170192. https://pubmed.ncbi.nlm.nih.gov/35170192/

  • Anti-cancer potential

    Speculative

    A 2024 study found reduced survivin expression and increased cell death in human glioblastoma cell lines. These cell-line findings do not establish treatment benefits in animals or patients.

    Suzuki, Kitanaka and Okada, Anticancer Research 2024;44:3875–3883. Human glioblastoma cell-line study. PMID 39197897. https://pubmed.ncbi.nlm.nih.gov/39197897/

  • Central mechanism

    Medium

    Acts on brain melanocortin receptors in animal models, though the FDA label calls the mechanism unknown.

    PMID 17958619 (Molinoff-era preclinical CNS overview, J Sex Med 2007) https://pubmed.ncbi.nlm.nih.gov/17958619/ ; VYLEESI label, Clinical Pharmacology https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

Benefits(6)

  • HSDD treatment (women)

  • Erectile dysfunction (men)

  • Sexual arousal (women)

  • Appetite suppression

  • Anti-cancer potential

  • Central mechanism

Key studies(5)

  1. Kingsberg SA et al.

    Obstet Gynecol

    2019

    n=1,247: significant desire improvement and distress reduction (p<.001)

  2. Simon JA et al.

    Obstet Gynecol

    2019

    52-week extension: sustained improvements, no new safety signals

  3. Rosen RC et al.

    Int J Impot Res

    2004

    Significant erectile responses at 4-6mg even in PDE5i non-responders

  4. Diamond LE et al.

    J Sex Med

    2006

    Significantly more moderate/high desire (p=.0114), improved satisfaction

  5. Suzuki S et al.

    Anticancer Res

    2024

    Reduced survivin, induced cell death via MC3R/MC4R. Enhanced chemo effects.

What research suggests over time

  • Hours-Days

    FDA labeling

    On-demand product (Vyleesi): single dose taken 45 min before sexual activity; not designed for chronic dosing.

  • Weeks 2-4

    RECONNECT trials

    Sustained sexual desire improvements with intermittent use in pre-menopausal HSDD trials.

  • Long-term

    Phase 3 RCT

    Continued safety and efficacy in Phase 3 (RECONNECT-1/2) for hypoactive sexual desire disorder. Common side effects: nausea, flushing, transient BP rise.

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Vyleesi (bremelanotide)
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(6)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • Hormone panel (testosterone, estradiol, LH, FSH)

    Optimal 600–900 ng/dL (men)

    Baseline hormone levels to track peptide effects.

    Lab normal 264–916 ng/dL (men)

  • Prolactin

    Optimal Under 12 ng/mL

    Some peptides affect prolactin; baseline needed.

    Lab normal 4–15 ng/mL (men)

  • PSA (prostate-specific antigen)

    Optimal Age-adjusted; trend matters more than absolute

    Baseline prostate marker — standard before initiating therapies affecting the HPG axis.

    Lab normal Under 4.0 ng/mL

  • Blood pressure + heart rate

    Cardiovascular baseline — blood pressure effects documented.

Ongoing tracking(4)

  • Hormone panel

    Every 6-8 weeks

    Track hormone level changes during protocol.

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic function monitoring.

    Lab normal ALT 7–56, AST 10–40 U/L

  • Prolactin

    Every 8 weeksOptimal Under 12 ng/mL

    Monitor for prolactin-related side effects.

    Lab normal 4–15 ng/mL (men)

  • Blood pressure + heart rate

    Every 4 weeks

    Blood pressure monitoring.

Retest schedule(5)

  1. Baseline

    critical

    Before starting

    Full baseline panel — establish reference values for all monitored markers.

  2. Early follow-up

    critical

    Week 4-6

    Spot-check for early changes — focus on glucose, liver enzymes, and any peptide-specific markers.

  3. Mid-protocol

    critical

    Week 12

    Comprehensive retest. Compare all markers to baseline.

  4. Ongoing

    standard

    Quarterly

    Continued monitoring during extended protocols.

  5. Post-protocol

    standard

    4-6 weeks after stopping

    Confirm return to baseline. Important for GH and metabolic peptides.

When to stop and reassess(6)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • Prolactin

    consult

    Above 25 ng/mL

    Consult an endocrinologist — possible prolactinoma or peptide effect.

  • PSA

    consult

    Velocity >0.75 ng/mL/year or new elevation

    Consult a urologist — rising PSA warrants evaluation.

  • Blood pressure

    consult

    Sustained >140/90

    Consult a provider — blood pressure effects documented.

Lab monitoring helps track your body's response to PT-141 (Bremelanotide). Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

A melanocortin receptor agonist studied for central effects on sexual desire — the RECONNECT trials (1,200+ women) showed significant improvements in desire, with a 52-week extension in 684 patients confirming sustained effects. Phase 3 trials for male erectile dysfunction are advancing, which could make PT-141 the first brain-acting sexual health treatment available to both sexes.

Estimated cost
$800-1,200/mo retail (Vyleesi); $100-200/mo compounding
FDA status
FDA-approved June 2019 (Vyleesi, NDA 210557). Indication: acquired generalized HSDD in premenopausal women. Max 1 dose/24h, 8 doses/month. Contraindicated in uncontrolled HTN/CVD. Not approved for men (Phase 2 initiated; Phase 3 planned). Palatin Technologies.
WADA status
Not explicitly listed by WADA
Prescribability
FDA-approved as Vyleesi (subcutaneous autoinjector) for premenopausal women with HSDD. Compounded formulations available for off-label use in men.
Availability
FDA-approved Vyleesi (subcutaneous autoinjector) via BlinkRx specialty pharmacy. ~$290/dose or ~$1,019/4-dose box. $0 copay assistance available. Compounded SC/sublingual/nasal formulations $50-150/mo for men and women.

International status

  • EU

    Not EMA-approved

  • US

    FDA-approved (Vyleesi)

  • Canada

    Not approved

  • Australia

    Not TGA-approved

Regulatory timeline(4)

  1. 2004
    Phase 2 ED studiesDiamond and Rosen studies in healthy males and ED patients
  2. 2006
    Phase 2 female arousalDiamond et al. RCT in premenopausal women
  3. 2019-06
    FDA approval (Vyleesi)NDA 210557 for HSDD in premenopausal women
  4. Ongoing
    Phase 3 male ED advancingPalatin Technologies pursuing male indication

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

How does it differ from Viagra?

Acts centrally via MC3R/MC4R in brain (dopamine modulation) vs peripheral vasodilation. Targets desire not just mechanics. Works in PDE5i non-responders.

Approved for men?

No, FDA-approved only for premenopausal women with HSDD. Phase 2 showed efficacy in men. Phase 3 for male ED advancing. Compounded off-label available.

Side effects?

Nausea affected about 40%; 13% received antiemetic treatment and 8% discontinued because of nausea. Flushing affected 20% and headache 11%. Transient BP +6/3mmHg. Rare focal hyperpigmentation 1%.

How fast does it work?

Administer 45+ min before activity. Onset ~30 min. Half-life ~2.7h. BP/HR effects resolve within 12h.

Skin darkening?

About 1% with labeled use. Risk increases significantly with daily use (>1/3 in studies). May be persistent. Higher risk in darker skin tones.